Nikhil Lalwani, President and CEO of ANI Pharmaceuticals Inc., filed a Form 4 on August 26, 2026, disclosing the sale of 5,400 shares of common stock on August 25, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: 5,400 shares of ANI Pharmaceuticals common stock disposed of on August 25, 2026.
  • Weighted average price: $74.3 per share, with individual trades ranging from $73.58 to $74.61.
  • Remaining ownership: Lalwani directly held 344,489 shares following the reported transaction.
  • 10b5-1 plan: The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Lalwani on May 26, 2026.
  • Reporting person role: Lalwani is identified as both a Director and Officer (President and CEO) of the issuer.

ANI Pharmaceuticals CEO Transaction Details and Plan Context

According to the filing, Nikhil Lalwani, serving as President and CEO of ANI Pharmaceuticals Inc. (NASDAQ:ANIP), disposed of 5,400 shares of the company's common stock on August 25, 2026. The transaction was recorded under transaction code "S," indicating a sale. The shares were sold in multiple trades at prices ranging from $73.58 to $74.61, and the filing reports a weighted average sales price of $74.3 per share.

The filing notes that the sales were carried out pursuant to a Rule 10b5-1 trading plan that Lalwani adopted on May 26, 2026. The Form 4 box indicating a transaction made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) was checked. Following the reported sale, Lalwani's direct beneficial ownership stood at 344,489 shares of common stock, according to the filing. No derivative securities transactions were reported in Table II.

The Form 4 was signed on August 26, 2026, by attorney-in-fact Meredith W. Cook on behalf of Nikhil Lalwani. The filing covers only non-derivative securities and lists no indirect beneficial ownership positions.

What Was Disclosed

The filing discloses a single sale of 5,400 shares of ANI Pharmaceuticals common stock by President and CEO Nikhil Lalwani on August 25, 2026, at a weighted average price of $74.3, executed under a Rule 10b5-1 plan adopted May 26, 2026, leaving him with 344,489 shares directly held.